Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

Allogeneic CAR-iNKT Cell Therapy Targeting CLDN18.2 in Gastric and Pancreatic Cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

CHClinton M. HeinzeELElisa LandoniMFMichelle Ferguson

Discussion

Loading...

Member takes

Overview

Novel allogeneic CAR-iNKT cell therapy demonstrates potent cytotoxic activity against CLDN18.2-positive tumors, suggesting effective treatment for solid cancers.

Key Points

  • This research aims to develop an allogeneic CAR-iNKT cell therapy targeting CLDN18.2 in gastric and pancreatic cancers, assessing its effectiveness.
  • Isolated iNKT cells from healthy donor PBMCs and activated them.
  • Transduced cells to express CLDN18.2 CAR, with IL-12-TM co-expression.
  • Expanded cells in culture and evaluated cytotoxic activity against CLDN18.2-positive cancer lines using a serial tumor re-challenge assay.
  • CLDN18.2 CAR-iNKT cells showed strong and lasting cytotoxic effects against tumor cells.
  • Co-expression of IL-12-TM enhanced cell persistence and response durability under tumor stress.
  • Supporting potential of this therapy for targeting gastric and pancreatic cancers.

Cite This Study

Heinze et al. (2026) studied this question.

synapsesocial.com/papers/69d1fe18a79560c99a0a4a6ehttps://doi.org/10.1158/1538-7445.am2026-140
View Full Paper
Ask AI
Bookmark
Share